Article
Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.
Internal medicine (Tokyo, Japan) - 15 Feb 2021
Nishima Shunichi, Miyanaga Akihiko, Saito Sho, Yuasa Mizuki, Takahashi Satoshi, Kashiwada Takeru, Sugano Teppei, Noro Rintaro, Minegishi Yuji, Terasaki Yasuhiro, Saito Yoshinobu, Kubota Kaoru, Seike Masahiro, Gemma Akihiko
Abstract excerpt
Osimertinib is the standard treatment for epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer. However, drug-induced interstitial lung disease (ILD) is recognized as a serious adverse event associated with EGFR-tyrosine kinase inhibitors (TKIs). We herein report a 78-year-old woman with stage IV lung adenocarcinoma harboring an EGFR L858R mutation on exon 21 who received rechallenge...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.